Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B

Ratings ESG MSCI

Ratings Compass Therapeutics, Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: Compass Therapeutics, Inc.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses: Compass Therapeutics, Inc.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Rating Financials

Compass Therapeutics, Inc. SectorUnited States

Fundamentals

-

Growth

Revenue growth

-

EPS growth

FCF growth

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Compass Therapeutics, Inc. SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Compass Therapeutics, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Compass Therapeutics, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Compass Therapeutics, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
342M -
B
- -
70.88B
AAA
62.49B
A
26.34B
AAA
26.21B -
BBB
- -
24.13B - - - -
20.72B
A
15.69B
AA
14.46B
BB
14.24B - - - -
Average 27.55B
A
Weighted average by Cap.
A
  1. Stock Market
  2. Stocks
  3. CMPX Stock
  4. Ratings Compass Therapeutics, Inc.
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!